JSS Sustainable Equity - Future Health P CHF acc

Reference Data

ISIN LU2041625497
Valor Number 49498046
Bloomberg Global ID
Fund Name JSS Sustainable Equity - Future Health P CHF acc
Fund Provider J. Safra Sarasin Investmentfonds AG Basel, Switzerland
Phone: +41 58 317 44 44
Web: www.jsafrasarasin.com
Fund Provider J. Safra Sarasin Investmentfonds AG
Representative in Switzerland J. Safra Sarasin Investmentfonds AG
Basel
Phone: +41 58 317 44 00
Distributor(s) Bank J. Safra Sarasin AG
Basel
Phone: +41 58 317 44 00
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** The investment objective of the fund is to achieve long-term capital growth. The Reference Currency of the Sub-Fund is the US Dollar (USD).
Peculiarities

Fund Prices

Current Price * 81.19 CHF 16.04.2025
Previous Price * 81.68 CHF 15.04.2025
52 Week High * 102.21 CHF 16.07.2024
52 Week Low * 79.98 CHF 11.04.2025
NAV * 81.19 CHF 16.04.2025
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 113,963,908
Unit/Share Assets *** 11,097,070
Trading Information SIX

Performance

YTD Performance -12.27% 31.12.2024
16.04.2025
1 month -14.80% 17.03.2025
16.04.2025
3 months -14.89% 16.01.2025
16.04.2025
6 months -16.41% 16.10.2024
16.04.2025
1 year -13.51% 16.04.2024
16.04.2025
2 years -19.86% 17.04.2023
16.04.2025
3 years -30.56% 19.04.2022
16.04.2025
5 years -14.00% 16.04.2020
16.04.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

UnitedHealth Group Inc 7.15%
Danaher Corp 6.12%
Eli Lilly and Co 6.11%
Gilead Sciences Inc 4.95%
Sanofi SA 4.93%
Johnson & Johnson 4.84%
Boston Scientific Corp 4.59%
Novo Nordisk AS Class B 4.53%
AbbVie Inc 4.34%
AstraZeneca PLC 4.03%
Last data update 28.02.2025

Cost / Risk

TER 1.98%
TER date 31.10.2024
Performance Fee ***
PTR
Max. Management Fee *** 2.00%
Ongoing Charges *** 1.97%
SRRI ***
SRRI date *** 31.03.2025

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)